Local News

• Insecticide Movento(R) approved in United States and Canada  The new insecticidal active ingredient spirotetramat from Bayer CropScience has been granted regulatory approval in the strategically important markets in the United States and Canada. Spirotetramat will be marketed worldwide under the brand name Movento(R).
  Bayer July 03, 2008  
• Adolor provides update on Entereg(R) (alvimopan) OBD Program  Adolor Corporation issued an update on the Entereg(R) (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline. The FDA has concluded that clinical investigations relating to alvimopan in OBD may now proceed.
  Adolor Corporation July 03, 2008  
• OSI Pharmaceuticals announces conversion period for Convertible Notes  OSI Pharmaceuticals announced that its 2% Convertible Senior Notes due 2025 are now convertible at the option of the holders and will remain convertible through September 30, 2008, the last trading day of the current fiscal quarter, as provided for in the Indenture governing the notes.
  OSI Pharmaceuticals, Inc. July 03, 2008  
• Wyeth and Progenics receive approval from European Commission for RELISTOR  Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals announced that the companies have received marketing approval for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the European Commission.
  Progenics Pharmaceuticals, Inc. July 03, 2008  
• Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen  Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen's hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in 3Q 2008.
  Bayer July 02, 2008  
• Summary judgment granted for SEROQUEL patent litigation in the US  AstraZeneca announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries and Sandoz alleging infringement of AstraZeneca's patent.
  AstraZeneca July 02, 2008  
• Thermo Fisher Scientific acquires Open Biosystems, creating unmatched RNAi platform  Thermo Fisher Scientific announced that it has acquired Open Biosystems, a provider of RNA interference (RNAi), gene expression and protein detection products for life science research and drug discovery and development. The acquisition expands the company's leadership position in the RNAi field.
  Thermo Fisher Scientific Inc. July 02, 2008  
• Monsanto Company completes acquisition of Semillas Cristiani Burkard  Monsanto announced that it has completed its proposed acquisition of Marmot, which operates Semillas Cristiani Burkard (SCB), a privately-held seed company headquartered in Guatemala City, Guatemala. SCB is the leading Central American corn seed company focused on hybrid corn production.
  Monsanto Company July 02, 2008  
• FDA approves PROMUS Everolimus-Eluting Coronary Stent System  Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved the PROMUS(TM) Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The PROMUS Stent is a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary Stent System.
  Boston Scientific Corporation July 02, 2008  
• National cancer experts meet in Louisville to discuss future of cancer care  A panel of national cancer experts discussed issues surrounding the disease during a symposium entitled "Discovery to Delivery: A Public Forum about the Future of Cancer Research." The event was hosted by the University of Louisville's James Graham Brown Cancer Center and Friends of Cancer Research.
  Business First of Louisville July 02, 2008  Ben Adkins

   (next 10 articles)